Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE MS
NCT00725985Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Dec 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of cladribine in clinically isolated syndrome (CIS) (3 arms), sponsored by EMD Serono. Primary endpoint: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion at 96 weeks. Started Dec 2008; status: completed.
02
Drugs
cladribine
03
Conditions
clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT00725985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00725985.